melphalan and Rhabdoid-Tumor

melphalan has been researched along with Rhabdoid-Tumor* in 1 studies

Other Studies

1 other study(ies) available for melphalan and Rhabdoid-Tumor

Article	Year
Long-term survival after autologous peripheral blood stem cell transplantation in two patients with malignant rhabdoid tumor of the kidney. Pediatric blood & cancer, 2009, Volume: 52, Issue:7 A 5-month-old male with stage II malignant rhabdoid tumor of the kidney (MRTK) and a 24-month-old male with stage III MRTK were treated with surgical resection of tumors and chemotherapy of alternating ICE (ifosfamide, carboplatin, and etoposide) and VDC (vincristine, doxorubicin, and cyclophosphamide), followed by high-dose chemotherapy using etoposide, carboplatin, and melphalan with autologous hematopoietic stem cell transplantation (SCT). Two patients have been alive without any evidence of disease for 30 and 37 months after diagnosis, respectively, and require no medication. Consolidation with SCT should be further studies for selected patients with high-risk MRTK. Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infant; Kidney Neoplasms; Male; Melphalan; Prognosis; Rhabdoid Tumor; Survival Rate; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine	2009

Article

Year

Long-term survival after autologous peripheral blood stem cell transplantation in two patients with malignant rhabdoid tumor of the kidney.

Pediatric blood & cancer, 2009, Volume: 52, Issue:7

A 5-month-old male with stage II malignant rhabdoid tumor of the kidney (MRTK) and a 24-month-old male with stage III MRTK were treated with surgical resection of tumors and chemotherapy of alternating ICE (ifosfamide, carboplatin, and etoposide) and VDC (vincristine, doxorubicin, and cyclophosphamide), followed by high-dose chemotherapy using etoposide, carboplatin, and melphalan with autologous hematopoietic stem cell transplantation (SCT). Two patients have been alive without any evidence of disease for 30 and 37 months after diagnosis, respectively, and require no medication. Consolidation with SCT should be further studies for selected patients with high-risk MRTK.

Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infant; Kidney Neoplasms; Male; Melphalan; Prognosis; Rhabdoid Tumor; Survival Rate; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine

2009